{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:49:41Z","timestamp":1764172181928},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.imlet.2016.02.014","type":"journal-article","created":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T22:06:14Z","timestamp":1456351574000},"page":"113-123","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"172","author":[{"given":"Swati","family":"Sikaria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojtaba","family":"Akhtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2016.02.014_bib0005","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin)","volume":"238","author":"Farber","year":"1948","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.imlet.2016.02.014_bib0010","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.imlet.2016.02.014_bib0015","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"May (9)","key":"10.1016\/j.imlet.2016.02.014_bib0020","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"M\u00f6ricke","year":"2008","journal-title":"Blood"},{"issue":"February (3)","key":"10.1016\/j.imlet.2016.02.014_bib0025","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","article-title":"Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia","volume":"109","author":"Moghrabi","year":"2007","journal-title":"Blood"},{"issue":"April (8)","key":"10.1016\/j.imlet.2016.02.014_bib0030","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"issue":"3\u20134","key":"10.1016\/j.imlet.2016.02.014_bib0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.beha.2014.10.006","article-title":"Will novel agents for ALL finally change the natural history?","volume":"27","author":"Douer","year":"2014","journal-title":"Best Pract. Clin. Haematol."},{"issue":"January\u2013February (1)","key":"10.1016\/j.imlet.2016.02.014_bib0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4161\/mabs.26632","article-title":"Methods for site-specific drug conjugation to antibodies","volume":"6","author":"Behrens","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.imlet.2016.02.014_bib0045","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/pbc.25462","article-title":"CD19: a multifunctional immunological target molecule and its implications for B lineage acute lymphoblastic leukemia","volume":"62","author":"Weiland","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.imlet.2016.02.014_bib0050","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.imlet.2016.02.014_bib0055","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.4049\/jimmunol.180.7.4561","article-title":"Dendritic cell-dependent inhibition of B cell proliferation requires CD22","volume":"180","author":"Santos","year":"2008","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.imlet.2016.02.014_bib0060","first-page":"325","article-title":"CD52 antigen\u2013a review","volume":"7","author":"Domaga\u0142a","year":"2001","journal-title":"Med. Sci. Monit."},{"issue":"6","key":"10.1016\/j.imlet.2016.02.014_bib0065","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.imlet.2016.02.014_bib0070","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.imlet.2016.02.014_bib0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leuk. Res."},{"issue":"26","key":"10.1016\/j.imlet.2016.02.014_bib0080","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.imlet.2016.02.014_bib0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12288-012-0216-1","article-title":"Expression of CD20 in B cell precursor acute lymphoblastic leukemia","volume":"30","author":"Kumar","year":"2014","journal-title":"Indian J. Hematol. Blood Transfus."},{"issue":"6","key":"10.1016\/j.imlet.2016.02.014_bib0090","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"24","key":"10.1016\/j.imlet.2016.02.014_bib0095","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome\u2013negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"JCO"},{"key":"10.1016\/j.imlet.2016.02.014_bib0100","unstructured":"S\u00e9bastien, et al., Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study, ASH Plenary (2005)."},{"key":"10.1016\/j.imlet.2016.02.014_bib0105","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J. Immunol."},{"issue":"11\u201312","key":"10.1016\/j.imlet.2016.02.014_bib0110","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.molimm.2009.04.009","article-title":"Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20","volume":"46","author":"Du","year":"2009","journal-title":"Mol. Immunol."},{"issue":"10","key":"10.1016\/j.imlet.2016.02.014_bib0115","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"JCO"},{"issue":"21","key":"10.1016\/j.imlet.2016.02.014_bib0120","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood.V122.21.2664.2664","article-title":"Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive acute lymphoblastic leukemia (ALL)","volume":"122","author":"Jabbour","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2016.02.014_bib0125","doi-asserted-by":"crossref","unstructured":"A.T. Fathi, R. Chen, T.M. Trippett, et al., Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SG N-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma, (ASH Abstract 2014).","DOI":"10.1182\/blood.V124.21.963.963"},{"key":"10.1016\/j.imlet.2016.02.014_bib0130","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.imlet.2016.02.014_bib0135","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19\u00d7CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"L\u00f6ffler","year":"2000","journal-title":"Blood"},{"issue":"June (26)","key":"10.1016\/j.imlet.2016.02.014_bib0140","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.imlet.2016.02.014_bib0145","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody Blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"53","author":"Topp","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"36","key":"10.1016\/j.imlet.2016.02.014_bib0150","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"JCO"},{"issue":"January (1)","key":"10.1016\/j.imlet.2016.02.014_sbref0155a","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.imlet.2016.02.014_sbref0155b","article-title":"Factors influencing outcomes in patients (Pts) with relapsed\/refractory b-precursor acute lymphoblastic leukemia (r\/r ALL) treated with blinatumomab in a phase 2 study","volume":"33","author":"Kantarjian","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.imlet.2016.02.014_bib0160","doi-asserted-by":"crossref","unstructured":"N. G\u00f6kbuget, H. Dombret, et al., long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL), ASH Abstract (2015).","DOI":"10.1182\/blood.V126.23.680.680"},{"key":"10.1016\/j.imlet.2016.02.014_bib0165","unstructured":"Martinelli, et al., Complete Molecular and Hematologic Response in Adult Patients with Relapsed\/Refractory (R\/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA), ASH Abstract (2015)."},{"key":"10.1016\/j.imlet.2016.02.014_bib0170","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.imlet.2016.02.014_bib0175","doi-asserted-by":"crossref","first-page":"e61338","DOI":"10.1371\/journal.pone.0061338","article-title":"CD19CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia","volume":"8","author":"Davila","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.imlet.2016.02.014_bib0180","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"NEJM"},{"issue":"9967","key":"10.1016\/j.imlet.2016.02.014_bib0185","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"224","key":"10.1016\/j.imlet.2016.02.014_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19\u201328z CAR t cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.imlet.2016.02.014_bib0195","doi-asserted-by":"crossref","unstructured":"R.A. Gardner, et al., T Cell Products of Defined CD4:CD8Composition and Prescribed Levels of CD19CAR\/Egfrt Transgene Expression Mediate Regression of Acute Lymphoblastic Leukemia in the Setting of Post-Allohsct Relapse, ASH Abstract (2014).","DOI":"10.1182\/blood.V124.21.3711.3711"},{"issue":"October (17)","key":"10.1016\/j.imlet.2016.02.014_bib0200","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived C-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.imlet.2016.02.014_bib0205","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/leu.2011.206","article-title":"The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells","volume":"26","author":"de Vries","year":"2012","journal-title":"Leukemia"},{"issue":"March (5)","key":"10.1016\/j.imlet.2016.02.014_bib0210","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.imlet.2016.02.014_bib0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00262-004-0572-2","article-title":"Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22","volume":"54","author":"DiJoseph","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.imlet.2016.02.014_bib0220","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1158\/1078-0432.CCR-05-1905","article-title":"Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin\u2019s B-cell lymphoma","volume":"12","author":"DiJoseph","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.imlet.2016.02.014_bib0225","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of Inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"April (4)","key":"10.1016\/j.imlet.2016.02.014_bib0230","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.imlet.2016.02.014_bib0235","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1349-7006.2012.02241.x","article-title":"Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"103","author":"Ogura","year":"2012","journal-title":"Cancer Sci."},{"issue":"15","key":"10.1016\/j.imlet.2016.02.014_bib0240","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"issue":"5s","key":"10.1016\/j.imlet.2016.02.014_bib0245","article-title":"Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients and as salvage therapy for adult with R\/R acute lymphoblastic leukemia [abstract]","volume":"32","author":"Jabbour","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.imlet.2016.02.014_bib0250","doi-asserted-by":"crossref","unstructured":"E. Jabbour, S. O\u2019Brien, D.A. Thomas, et al., Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Salvage Therapy for Adult Patients with Refractory\/Relapse (R\/R) Acute Lymphoblastic Leukemia (ALL) [abstract], ASH (2014).","DOI":"10.1016\/j.clml.2015.04.006"},{"issue":"22","key":"10.1016\/j.imlet.2016.02.014_bib0255","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a children's oncology group pilot study","volume":"26","author":"Raetz","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.imlet.2016.02.014_bib0260","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/pbc.25454","article-title":"Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children\u2019s Oncology Group (COG) study ADVL04P2","volume":"62","author":"Raetz","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.imlet.2016.02.014_bib0265","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.3324\/haematol.2014.120220","article-title":"Vincristine, dexamethasone and epratuzumab for older relapsed\/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study","volume":"100","author":"Chevallier","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.imlet.2016.02.014_bib0270","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.12778","article-title":"SWOG S0910: a phase 2 trial of clofarabine\/cytarabine\/epratuzumab for relapsed\/refractory acute lymphocytic leukemia","volume":"165","author":"Advani","year":"2014","journal-title":"Brit. J. Haematol."},{"issue":"12","key":"10.1016\/j.imlet.2016.02.014_bib0275","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/cncr.21901","article-title":"Activity of alemtuzumab in patients with CD52-positive acute leukemia","volume":"106","author":"Tibes","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.imlet.2016.02.014_bib0280","doi-asserted-by":"crossref","first-page":"5930","DOI":"10.1182\/blood-2010-01-262006","article-title":"A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL","volume":"116","author":"Nijmeijer","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.imlet.2016.02.014_bib0285","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/pbc.22209","article-title":"A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children\u2019s Oncology Group report","volume":"53","author":"Angiolillo","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.imlet.2016.02.014_bib0290","article-title":"Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a cancer and leukemia group B study (CALGB 10102)","volume":"114","author":"Stock","year":"2009","journal-title":"Bloo"},{"issue":"4","key":"10.1016\/j.imlet.2016.02.014_bib0295","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/ejh.12154","article-title":"Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study","volume":"91","author":"Gorin","year":"2013","journal-title":"Eur. J. Haematol."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247816300232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247816300232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T15:44:07Z","timestamp":1718379847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247816300232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":60,"alternative-id":["S0165247816300232"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2016.02.014","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2016.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}